A Nature biotechnology report cited an analysis of the 25 most active VC firms that shows less than 1% of senior level investment teams have partners from underrepresented racial and ethnic groups. McKinsey data also shows disparities in funding women’s health outside of oncology with less than 2 percent of the current healthcare pipeline including these conditions despite women being half of the global population. Attend this session to hear how VCs, diverse founders, and biotech executives are approaching investment opportunities to reduce these disparities.